Breaking News, Promotions & Moves

CureVac Appoints Chief Financial Officer

Axel Sven Malkomes offers 3+ decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries.

Author Image

By: Charlie Sternberg

Associate Editor

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.   Malkomes brings over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries.   “Axel’s appointment corresponds with a significant milestone in CureVac’s evolution,” said Dr. Alexander Zehnder, Chief...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters